UBS Raises Viatris (VTRS) Price Target as Cost Savings and Growth Outlook Improve

Core Insights - Viatris Inc. (NASDAQ: VTRS) is recognized as one of the 13 Best March Dividend Stocks to Buy [1] - UBS has raised its price target for Viatris from $18 to $20, maintaining a Buy rating, citing the company's achievement of Q4 cost-saving goals and positive FY26 guidance [2] - The company reported total revenue of $14.3 billion and adjusted EBITDA of $4.2 billion for Q4 2025, indicating strong financial performance [3] Financial Performance - Viatris achieved total revenue of $14.3 billion and adjusted EBITDA of $4.2 billion in Q4 2025, reflecting the overall strength of the business [3] - The company returned over $1 billion to shareholders through dividends and share repurchases during the year [4] Growth Outlook - Viatris expects to generate approximately $650 million in gross cost savings over three years, with up to $250 million reinvested into growth initiatives [5] - The company is preparing for a potential FDA reinspection of its Indore facility, implementing operational redundancies to ensure continuity and stability [5] Pipeline Progress - Five Phase III studies have delivered positive results, marking an important milestone for the company [4] - Enrollment in key programs, including cenerimod and selatogrel, is progressing and expected to be completed in 2026 [4] Strategic Initiatives - The completion of 60 regional transactions, including the acquisition of Aculys Pharma in Japan, is part of Viatris' broader strategic plan [4]